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a b s t r a c t
Human herpesvirus 6 (HHV-6), which replicates abundantly in T cells, belongs to the Roseolovirus genus
within the betaherpesvirus subfamily. Members of the Roseolovirus genus encode seven unique genes,
U20, U21, U23, U24, U24A, U26, and U100. The present study focused on one of these, U23, by analyzing
the characteristics of its gene product in HHV-6A-infected cells. The results indicated that the U23
protein was expressed at the late phase of infection as a glycoprotein, but was not incorporated into
virions, and mostly stayed within the trans Golgi network (TGN) in HHV-6A-infected cells. Furthermore,
analysis using a U23-defective mutant virus showed that the gene is nonessential for viral replication
in vitro.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Human herpesvirus (HHV)6 is closely related to HHV-7, and
both viruses belong to the Roseolovirus genus of the betaherpes-
virus subfamily, which is characterized by growth in T lympho-
cytes, high prevalence, and association with febrile illness (Caselli
and Di Luca, 2007; Nicholas, 1996). HHV-6 has been classiﬁed into
two variants, HHV-6A and HHV-6B, based on cell tropism and
genetic and antigenic differences (Aubin et al., 1991; Campadelli-
Fiume et al., 1993; Salahuddin et al., 1986; Wyatt et al., 1990). More
recently, they were re-classiﬁed into two species, HHV-6A and
HHV-6B, on the basis of distinct biological features (see the Virus
Taxonomy List 2011), although the sequence identity between
the HHV-6A and -6B is almost 90% over their entire genome
(Dominguez et al., 1999; Gompels et al., 1995; Isegawa et al.,
1999). HHV-6B causes exanthem subitum in primary infections
(Yamanishi et al., 1988), and is ubiquitous, with more than 90% of
adults having antibodies against it (Okuno et al., 1989; Ward et al.,
1993). However, the diseases caused by HHV-6A are unknown.
Roseolovirus genomes encode seven unique genes, U20, U21, U23,
U24, U24A, U26, and U100. The U100 gene encodes the gQ protein,
which is important for virus entry (Akkapaiboon et al., 2004;
Kawabata et al., 2011; Maeki et al., 2013; Mori, 2009; Mori et al.,
2003a, 2003b; Tang et al., 2010,2011). HHV-7 U21 binds to class I
major histocompatibility complex (MHC) molecules and down-
regulates their expression on the cell surface (May et al., 2010).
HHV-6 A U24 mediates a rapid relocalization of cluster-determinant
3 (CD3) and T-cell receptor (TCR) proteins from the cell surface to
early endosomes (Sullivan and Coscoy, 2010). Furthermore, U24
mediates the downregulation of TCR and also the transferrin
receptor (TfR), through a PPXY motif near the amino terminus of
U24, suggesting a general block in early endosomal recycling
(Sullivan and Coscoy, 2008, 2010). U20 is responsible for HHV-6B
inhibition of TNF receptor-dependent signaling and apoptosis
(Kofod-Olsen et al., 2012). The U23 gene, however, has remained
largely uncharacterized. Therefore, in this study, we focused on the
HHV-6A U23 gene, and characterized the gene product in HHV-6
A-infected cells. We found that U23 is a glycoprotein expressed at
the late phase of infection that localizes mainly to the trans
Golgi network (TGN), but is not expressed in virions. Analysis of
U23-defective mutant viruses showed that this gene is nonessential
for viral replication in vitro.
Results
As shown in Fig. 1a, U23 is encoded in the unique region of the
HHV-6A genome (Dominguez et al., 1999; Gompels et al., 1995;
Isegawa et al., 1999). The predicted protein sequence encoded by
the U23 ORF is 236 amino acids long, and contains two hydro-
phobic regions, possibly a signal sequence and a transmembrane
domain.
To analyze the U23 gene product, we ﬁrst produced a mono-
speciﬁc antibody (ab) against the U23 protein, as described in the
“Materials and methods” section. The speciﬁcity of the obtained ab
was conﬁrmed using U23-expressing plasmid-transfected cells
(Fig. 1b). Next, its expression was examined in HHV-6A-infected cells.
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A protein of approximately 37 kDawas detected by the anti-U23 ab in
HHV-6A-infected cells, but not in mock-infected cells (Fig. 1b).
Next, we examined the kinetics of U23 protein expression. U23
was detected at 1 day post-infection (PI) and its expression was
gradually increased over 3 days PI (Fig. 2a). HHV-6A gQ1 was used
as a positive control for infection (Fig. 2a). To examine the kinetics
of infection in more detail, HHV-6A was infected with or without
phosphonoformic acid (PFA). In the presence of PFA, U23 protein
was not detected, and neither was gQ1, which is a late protein.
However, two other proteins, IE1 (immediate early) and U27
(early), were detected (Fig. 2b), indicating that U23 is a late
protein.
U23 is predicted to be a glycoprotein. Therefore, HHV-6A-
infected cell lysates were digested with endo H or PNGase F. As
expected, U23 expressed in HHV-6A-infected cells was digested
with both endoglycosidases, indicating that U23 is an N-linked
glycoprotein (Fig. 3). The gQ1 protein is also shown, as a positive
control for the digestion (Fig. 3).
As we found that U23 is a glycoprotein, we next examined
whether U23 is expressed in virions, because generally viral
glycoproteins that are expressed at the late phase are incorporated
into viral particles.
Unexpectedly and surprisingly, whereas gQ1-80K was detected
in virions, U23 was not, indicating that U23 is not an envelope
glycoprotein (Fig. 4).
Because U23 was not expressed in virions, even though it is a
late-phase glycoprotein, we examined its localization in HHV-6A-
infected cells. As predicted, it rarely colocalized with gB, which is
an envelope glycoprotein, nor did it colocalize with CD63 and
Lamp1. It mainly colocalized with TGN46 and, to a lesser degree,
with Calnexin. These results indicate that U23 is mainly found at
the TGN in infected cells (Fig. 5).
Next, we examined whether U23 is essential for virus growth. To
study this, we constructed a HHV-6A bacterial artiﬁcial chromosome
(BAC) with a U23 gene mutated to substitute tagg for methionine
residues (HHV-6ABACΔU23) (Fig. 6a), and transfected it into the
cells. The virus assembled from HHV-6ABACΔU23 appeared to be
identical to virus assembled from HHV-6ABAC (Fig. 6c). Its revertant
genome (HHV-6ABACΔU23rev) was also constructed, and virus was
reconstituted from this genome. To conﬁrmwhether U23 could have
been knocked out, a Western blot was performed using the virus-
infected cells. U23 was not detected in rHHV-6ABACΔU23-infected
cells, but it was detected in rHHV-6ABAC-infected cells, indicating
that U23 was not expressed in rHHV-6ABACΔU23-infected cells
(Fig. 6b). These results indicate that U23 is nonessential for virus
replication. Next, we compared the growth of rHHV-6ABACΔU23
with that of the original virus and its revertant virus. As shown in
Fig. 7, there were no differences in virus growth between rHHV-
6ABACΔU23, rHHV-6ABAC, and rHHV-6ABACΔU23rev, indicating
that U23 is not necessary for virus growth in vitro.
Discussion
The genus Roseolovirus encodes several unique genes (Caselli and
Di Luca, 2007; Nicholas, 1996), including the previously uncharacter-
ized HHV-6A U23. Bioinformatic predictions suggested that it was a
type I membrane-spanning protein. First, we investigated whether the
U23 ORF product was expressed in HHV-6A-infected cells by produ-
cing ab against U23. U23 was detected as an approximately 37 kDa
late-phase protein expressed in HHV-6A-infected cells. Furthermore,
complete digestion with endo H and PNGase F indicated that U23 was
an N-linked glycoprotein, although it was not incorporated into viral
particles. Generally, herpesvirus glycoproteins expressed at late phase
Fig. 1. HHV-6A-speciﬁc reactivity of anti-U23 antibody. (a) Schematic interpretation of the structure of HHV-6A U23. The arrow-shaped box represents the ORF, including
the N and C terminals. The dotted line represents the position of the immunogenic region used to produce the antibodies. The black-and-white-banded square represents the
predicted signal peptide and the dark square represents the predicted transmembrane domain. SOSUI was used to conduct sequence analyses (〈http://bp.nuap.nagoya-u.ac.
jp/sosui/sosuisignal/sosuisignal_submit.html〉). (b) HSB-2 cells were mock-infected or infected with HHV-6A strain GS. The cells were lysed in RIPA buffer (containing 0.1%
SDS, 1% NP40) at 48 h post-infection. The 293T cells were transfected with plasmid pCAGGS-U23, or plasmid pCAGGS as a negative control. The cells were lysed in TNE buffer
(containing 1% NP40) at 48 h post-infection. Lysates were resolved by SDS-PAGE with 13% polyacrylamide under non-reducing conditions, and electrotransferred to
polyvinylidene diﬂuoride (PVDF) membranes. The blots were then incubated with anti-U23 polyclonal antibody.
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Fig. 2. Kinetic analysis of U23 expression. (a) HSB-2 cells were infected with strain GS and then harvested at 1, 2, and 3 days post-infection. The cells were lysed in RIPA
buffer. Lysates were resolved by SDS-PAGE with 13%, 7.5% or 10% polyacrylamide under non-reducing or reducing conditions, and electrotransferred to polyvinylidene
diﬂuoride (PVDF) membranes. The blots were incubated with anti-U23, anti-gQ1, or anti-α-tubulin antibodies. (b) HSB-2 cells were infected with HHV-6A strain GS in the
presence of PFA (300 μg ml1) or in the absence at 48 h post-infection. The cells were lysed in RIPA buffer. Lysates were resolved by SDS-PAGE with 13% or 7.5%
polyacrylamide under non-reducing or reducing conditions, and electrotransferred to PVDF membranes. The blots were then incubated with anti-U23 polyclonal antibody or
anti-U27, anti-IE1, anti-gQ1, or anti-α-tubulin monoclonal antibodies.
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of infection, are incorporated into virions, where they work as
envelope glycoproteins. Interestingly, U23 did not appear to be an
envelope glycoprotein. Furthermore, we found that it did not coloca-
lize with gB and CD63, which are incorporated into viral particles, nor
did it colocalize with lamp 1, which is usually detected at endosomes.
It is interesting that U23 stays in the TGN and is not transported to
viral budding sites as are almost all of the other viral proteins. Since it
was found to be localized mainly to the TGN, U23 may be involved in
the modiﬁcation of the cellular machinery in HHV-6A-infected cells,
perhaps in the modiﬁcation of sorting or recycling of cargo proteins.
As the U23 gene is unique to the Roseolovirus genus, it was
thought not to be a core gene for virus replication. As predicted,
U23-defective mutant viruses were reconstituted from the gen-
ome and growth of the mutants appeared to be identical to that of
the original type virus in vitro.
However, the function of U23 in HHV-6A infection is still
unknown. U23 may play an important role in in vivo virus
replication and Roseolovirus-speciﬁc pathogenesis. Recently, an
animal model for HHV-6A has been shown (Tanner et al., 2013).
The model would be useful to analyze HHV-6A pathogenesis.
Materials and methods
Cells and virus strains
The human T-cell lines JJhan and HSB-2 were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium with 8%
fetal bovine serum, and 293 T cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) with 8% fetal bovine serum.
Umbilical cord blood mononuclear cells (CBMCs) were prepared
as previously described (Dhepakson et al., 2002). CBMCs were
provided by K. Adachi (Minoh Hospital, Minoh, Japan) and
H. Yamada (Kobe University Graduate School of Medicine, Kobe,
Japan) and purchased from the Cell Bank of the RIKEN BioResource
Center, Japan. The HHV-6 A strain GS was propagated and titrated
in HSB-2 cells. Virions were puriﬁed as described previously (Mori
et al., 2008). Phosphonoformic acid (PFA) inhibits viral DNA
synthesis. HSB-2 cells were infected with HHV-6A strain GS,
cultured in medium with PFA (300 mg ml1), and harvested at
48 h PI. Regarding CBMC usage, it was approved by the ethical
committees of Kobe University Graduate School of Medicine.
Antibodies
Rabbit antisera speciﬁc for HHV-6A protein U23 were gener-
ated from rabbits injected with glutathione S-transferase (GST)–
U23 fusion protein, and boosted with U23 protein that GST-tag had
been cleaved. The primer pair AU23bamF64 (5′-ACCGGATCCAC-
TACAGAAGTTTCGGC-3′) and AU23xhoR489 (5′-ACCCTCGAGGA-
CTTGAACAGTATCAG-3′) was used for PCR ampliﬁcation. The PCR
product was then inserted in-frame into the pGEX6P-1 bacterial
expression vector (GE Healthcare Bio-Sciences, Piscataway, NJ) via
the BamHI and XhoI sites (underlined). The resultant GST-U23
fusion protein was expressed in Escherichia coli, afﬁnity puriﬁed,
and used to produce abs in rabbits. For cleavage of GST-tagged
protein, PreScission Protease was purchased from GE Healthcare.
Eluted GST-tagged U23 protein was digested with PreScission
Protease as speciﬁed by the manufacturer.
The monoclonal antibodies (Mabs) for HHV-6A gB (OHV-1), gQ1
(AgQ-119), IE1, and U27 were described previously (Akkapaiboon
et al., 2004; Huang et al., 2006; Okuno et al., 1992). Mabs were
purchased for α-tubulin (Sigma-Aldrich, Japan), calnexin (Abcam,
Cambridge, United Kingdom), CD63 (Sanquin Blood Supply, Amster-
dam, The Netherlands), and Lamp1 (Santa Cruz Biotechnology
(SCBT), Dallas, Texas). Polyclonal antibodies (Pabs) for TGN46 were
purchased from AbD Serotec, Oxford, United Kingdom. The following
secondary abs were used: Alexa Fluor 488 or 594-labeled donkey
anti-mouse, -sheep, or -rabbit immunoglobulin G (Molecular Probes-
Eugene, Oregon).
Immunoﬂuorescence assays
Indirect immunoﬂuorescence assays (IFA) were performed as
described previously (Dhepakson et al., 2002). Speciﬁc immuno-
ﬂuorescence was observed with a confocal laser scanning micro-
scope (OLYMPUS FV1000D).
Fig. 3. Glycosylation analysis of U23. HSB-2 cells were mock-infected or infected
with HHV-6A strain GS. The cells were harvested at 72 h post-infection. The cells
were lysed in RIPA buffer and digested with endo H (H) or PNGase F (F), resolved by
SDS-PAGE with 13% or 7.5% polyacrylamide under non-reducing conditions, and
electrotransferred to PVDF membranes. The blots were incubated with anti-U23
polyclonal antibody or anti-gQ1 monoclonal antibody.
Fig. 4. Western blot of puriﬁed HHV-6A virions. Puriﬁed HHV-6A virions were
resolved by SDS-PAGE with 13% or 7.5% polyacrylamide under non-reducing or
reducing conditions, and electrotransferred to polyvinylidene diﬂuoride (PVDF)
membranes. The blots were then incubated with anti-U23 polyclonal antibody or
anti-gQ1 monoclonal antibody. Strain GS-infected HSB-2 cells lysed at 48 h post-
infection were used as a positive control (HHV-6A).
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Fig. 5. Cellular localization of the U23 protein in HHV-6A-infected cells. HSB-2 cells were infected with strain GS. At 48 h post-infection, the cells were harvested for
immunoﬂuorescence analysis. Antibodies for U23, gB, CD63, Lamp1, Calnexin, or TGN46 were used, along with Hoechst 33342 for staining. Single sections are shown. Scale
bar: 5 μm.
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Western blotting
Western blotting was performed as described previously
(Akkapaiboon et al., 2004). The bound antibodies were detected
by chemiluminescence using Western blotting detection reagents
(Nacalai Tesque) and were visualized with the LAS minidetection
system (GE Healthcare).
Glycosidase digestion
For endoglycosidase digestion, endoglycosidase H (endo H) and
peptide N-glycosidase F (PNGase F) were purchased from New
England Biolabs. Lysed cells were resuspended in digestion buffer
and digested with endo H or PNGase F as speciﬁed by the
manufacturer (Akkapaiboon et al., 2004).
Plasmid constructions
HHV-6A U23 expression vectors were constructed by using plas-
mid pCAGGS. Plasmid pCAGGS was kindly provided by Dr. Jun-ichi
Miyazaki, Osaka University, Japan (Niwa et al., 1991). A DNA fragment
comprising the full-length U23 gene open reading frame was ampli-
ﬁed by PCR and inserted in-frame into pCAGGS via the NotI and
XhoI sites.
Fig. 6. Cytopathic effect and green ﬂuorescent protein (GFP) expression in reconstituted virus-infected cells. (a) At the top, the scale bar indicates the full length of the
HHV-6A U23 gene. The mutated parts of the methionine (M) site of the U23 gene sequence are also shown. (b and c) Umbilical cord blood mononuclear cells were infected
with rHHV-6ABAC or rHHV-6ABACΔU23 and then cocultured with JJhan cells to permit cell-to-cell infection. Cells were harvested 3 days after the start of cell-to-cell
infection. (b) The samples were resolved by SDS-PAGE with 13% or 7.5% polyacrylamide under non-reducing or reducing conditions, and electrotransferred to polyvinylidene
diﬂuoride (PVDF) membranes. The blots were reacted with anti-U23 polyclonal antibody, anti-gQ1 monoclonal antibody, or anti-α-tubulin monoclonal antibody. (c) Light
microscopic images are shown at the left, and GFP ﬂuorescence images in the same microscopic ﬁeld are shown at the right; rHHV-6ABAC (upper panel) and rHHV-
6ABACΔU23 (lower panel).
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Plasmid transfections
293 T cells were transfected by the calcium phosphate method
as described previously (Koshizuka et al., 2010).
Construction of HHV-6ABACΔU23 and its revertant
HHV-6ABACΔU23 and its revertant were constructed by using
modiﬁed two-step Red-mediated mutagenesis (Oyaizu et al., 2012;
Tang et al., 2010; Tischer et al., 2006). First, U23 was ampliﬁed from
HHV-6ABAC using the primers of 5′-accggatccgatccccctcggacgccgc-3′
and 5′-acagtcgacttagtaaaccgagatacag-3′. Next the PCR product was
digested with BamHI and SalI enzymes and cloned into pBluescript SK
() vector. Then, the codons for three methionine residues (No. 1, 38,
and 84) in the U23 gene were mutated using the QuikChange
lightning multi site-directed mutagenesis kit (Agilent Technologies)
and the primers: 5′-GGGCAATCGCAAAAACTAGGTTGTTCTTGTC-3′,
5′-GCGTCTAAAAACTAGGGAAACGGATGTATCG-3′ and 5′-ATCAGTCT-
TTTTAGGGTGACCTCTACG-3′, according to the manufacturer's proto-
col. Next, the ﬁrst Red-recombination was conducted by transforming
GS1853 E. coli harboring the G-1 clone of HHV-6ABAC with ampicillin




This recombination resulted in the replacement of the U23 gene in
HHV-6ABAC with ampicillin and sacB genes. Then, the secondary Red-
recombination was performed by transforming the resultant E. coli
with the U23 mutant gene fragment, which had been ampliﬁed
from pBluescript SK()U23m (described above), using the primers:
5′-CTGCTATCTTGGTGTGGGTGTG-3′ and 5′-TCATCTGCAAGTCTTTACA-
TCCCTCCTC-3′. The E. coli were selected on LB plates containing
chloramphenicol and 5% sucrose. The resultant BAC was designated
HHV-6ABACU23m. Its revertant was similarly constructed, as follows.
First, Red-recombination was performed by transforming GS1783
harboring HHV-6ABACΔU23 with ampicillin and sacB gene fragment.
Then, the resultant E. coliwere transformed with the U23 gene, which
was ampliﬁed from pBluescript SK()U23 (described above). The
resultant BAC was designated HHV-6ABACΔU23rev.
Viral growth assay
The viral growth assay was performed as described previously
(Oyaizu et al., 2012).
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